Table 1.
Summary of patients characteristics
| Patient number | Sex | Age, years | Diagnosis | Previous radiation | Previous cycles of chemotherapy | Number of aphereses | Times the processed total peripheral blood volume, a / b |
|---|---|---|---|---|---|---|---|
| Steady state mobilization, GI | |||||||
| 1 | m | 52 | MM | yes | 3× VelCD, 1× Cy 2 g/m2 | 3 | 4.1 / 13.1 |
| 2 | m | 44 | MM | none | 1× VelCD, 2× VelCD, | 2 | 3.4 / 7.1 |
| 1× Cy 3g/m2, 1× Cy 2 g/m2 | |||||||
| 3 | f | 45 | NHL | none | 5× R-CHOP, 6× R-FC, | 2 | 3.9 / 9.6 |
| 2× R-DHAP | |||||||
| 4 | f | 65 | MM | none | 3× VM, 1× Cy 3 g/m2 | 3 | 5.6 / 18.2 |
| 5 | m | 58 | MM | yes | 3× VelCD, 1× Cy 3 g/m2 | 3 | 4.4 / 14.7 |
| Mobilization with chemotherapy + G-CSF, GII | |||||||
| 6 | f | 69 | MM | yes | 1× VMP, 3× VelCD | 1 | 5.1 / – |
| 7 | m | 61 | NHL | yes | 6× R-CHOP | 1 | 3.6 / – |
| 8 | f | 68 | MM | none | none | 1 | 5.8 / – |
| 9 | m | 56 | MM | none | 3× VelCD | 1 | 4.9 / – |
| 10 | f | 54 | MM | none | 1× VelCD | 1 | 4.0 / – |
| 11 | m | 56 | MM | none | 4× VelCD | 1 | 4.3 / – |
| 12 | m | 61 | NHL | none | 6× R-CHOP | 1 | 4.2 / – |
| 13 | f | 60 | NHL, CNS | none | 4× MTX | 1 | 4.8 / – |
| 14 | m | 67 | NHL, CNS | none | 4× MTX | 1 | 3.5 / – |
m = male; f = female; MM = multiple myeloma; VelCD = Velcade, cyclophosphamide, dexamethasone; Cy = cyclophosphamide; R-CHOP = rituximab, doxorubicine, vincristine, prednisone; R-FC = rituximab, fludarabine, cyclophosphamide; R-DHAP = rituximab, dexamethasone, cytosine arabinoside, cisplatin; VM =Velcade, melphalan; VMP = Velcade, melphalan, prednisone; MTX = methotrexate; a = first apheresis after plerixafor application; b = summary of all aphereses with plerixafor application.